NCT05218603
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
Phase: N/A
Role: Collaborator
Start: Nov 30, 2021
Completion: Nov 6, 2025